Overview
Lissencephaly due to TUBA1A mutation (also known as TUBA1A-related lissencephaly or tubulinopathy-related lissencephaly) is a rare congenital brain malformation disorder caused by mutations in the TUBA1A gene, which encodes the alpha-1A tubulin protein. This protein is a critical component of microtubules, which play an essential role in neuronal migration during brain development. When TUBA1A is disrupted, neurons fail to migrate properly to their correct positions in the cerebral cortex, resulting in a smooth or incompletely folded brain surface (lissencephaly) rather than the normal pattern of gyri and sulci. The spectrum of brain malformations can range from classic lissencephaly (agyria-pachygyria) to more complex malformations including cerebellar hypoplasia, corpus callosum dysgenesis, and abnormalities of the hippocampus and basal ganglia. The condition primarily affects the central nervous system and manifests in the neonatal or early infantile period. Key clinical features include severe intellectual disability, intractable epilepsy (often with infantile spasms), significant motor impairment including spastic quadriplegia, microcephaly, and feeding difficulties. Many affected children have limited or absent speech development and require lifelong supportive care. The severity of symptoms generally correlates with the degree of cortical malformation observed on brain MRI. There is currently no cure or disease-modifying treatment for lissencephaly due to TUBA1A mutation. Management is supportive and symptomatic, focusing on seizure control with antiepileptic medications, physical and occupational therapy to optimize motor function, nutritional support (which may include gastrostomy tube placement for feeding difficulties), and management of respiratory complications. A multidisciplinary team approach involving neurologists, geneticists, developmental pediatricians, and rehabilitation specialists is essential for optimizing quality of life.
Clinical phenotype terms— hover any for plain English:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Lissencephaly due to TUBA1A mutation.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Lissencephaly due to TUBA1A mutation at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Lissencephaly due to TUBA1A mutation.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Lissencephaly due to TUBA1A mutation.
Community
No community posts yet. Be the first to share your experience with Lissencephaly due to TUBA1A mutation.
Start the conversation →Latest news about Lissencephaly due to TUBA1A mutation
No recent news articles for Lissencephaly due to TUBA1A mutation.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Lissencephaly due to TUBA1A mutation
What is Lissencephaly due to TUBA1A mutation?
Lissencephaly due to TUBA1A mutation (also known as TUBA1A-related lissencephaly or tubulinopathy-related lissencephaly) is a rare congenital brain malformation disorder caused by mutations in the TUBA1A gene, which encodes the alpha-1A tubulin protein. This protein is a critical component of microtubules, which play an essential role in neuronal migration during brain development. When TUBA1A is disrupted, neurons fail to migrate properly to their correct positions in the cerebral cortex, resulting in a smooth or incompletely folded brain surface (lissencephaly) rather than the normal pattern
How is Lissencephaly due to TUBA1A mutation inherited?
Lissencephaly due to TUBA1A mutation follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Lissencephaly due to TUBA1A mutation typically begin?
Typical onset of Lissencephaly due to TUBA1A mutation is neonatal. Age of onset can vary across affected individuals.